耐多药肺结核患者基线菌株二线抗结核药物耐药情况分析(4)
[14]Devasia RA，Blackman A，Gebretsadik T，et al. Fluoroquinolone resistance in Mycobacterium tuberculosis：The effect of duration and timing of ？覲uoroquinolone exposure[J].American Journal of Respiratory and Critical Care Medicine，2009，180(4)：365-370.
[15]Wu B，Zhang L，Liu Z，et al. Drug-resistant tuberculosis in Zhejiang Province，China：An updated analysis of time trends，1999-2013[J]. Glob Health Action，2017，10(1)：1293925.
[16]Chien JY，Chien ST，Chiu WY，et al. Moxifloxacin improves treatment outcomes in patients with ofloxacin-resistant multidrug-resistant tuberculosis[J]. Antimicrob Agents Chemother，2016，60 (8)：4708-4716.
[17]Kempker RR，Kipiani M，Mirtskhulava V，et al. Acquired drug resistance in mycobacterium tuberculosis and poor outcomes among patients with multidrug resistant tuberculosis[J]. Emerg Infect Dis，2015， 21(1)：992-1001.
[18]Domínguez J，Boettger EC，Cirillo D，et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis：A TBNET/RESIST-TB consensus statement[J]. Int J Tuberc Lung Dis，2016，20(1)：24-42.
[19]WHO. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs：Policy Guidance[Internet]. http：//www.who.int/tb/publications/lpa-mdr-diagnostics/en， 2017-11-21.
[20]Trauner A，Liu Q，Via LE，et al. The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy[J]. Genome Biol，2017，18(1)：71.
(收稿日期：2018-01-27), 百拇医药(何贵清 施伎蝉 吴联朋 蒋贤高)
[15]Wu B，Zhang L，Liu Z，et al. Drug-resistant tuberculosis in Zhejiang Province，China：An updated analysis of time trends，1999-2013[J]. Glob Health Action，2017，10(1)：1293925.
[16]Chien JY，Chien ST，Chiu WY，et al. Moxifloxacin improves treatment outcomes in patients with ofloxacin-resistant multidrug-resistant tuberculosis[J]. Antimicrob Agents Chemother，2016，60 (8)：4708-4716.
[17]Kempker RR，Kipiani M，Mirtskhulava V，et al. Acquired drug resistance in mycobacterium tuberculosis and poor outcomes among patients with multidrug resistant tuberculosis[J]. Emerg Infect Dis，2015， 21(1)：992-1001.
[18]Domínguez J，Boettger EC，Cirillo D，et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis：A TBNET/RESIST-TB consensus statement[J]. Int J Tuberc Lung Dis，2016，20(1)：24-42.
[19]WHO. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs：Policy Guidance[Internet]. http：//www.who.int/tb/publications/lpa-mdr-diagnostics/en， 2017-11-21.
[20]Trauner A，Liu Q，Via LE，et al. The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy[J]. Genome Biol，2017，18(1)：71.
(收稿日期：2018-01-27), 百拇医药(何贵清 施伎蝉 吴联朋 蒋贤高)